APHM Hôpital de la Timone

Marseille 13885

6 studies enrolling now · 18 studies all time

What they study most

Advanced Breast Cancer, Advanced Gastrointestinal Stromal Tumors, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Melanoma, Alzheimer's Disease, Any Solid Tumor, Chronic Cluster Headache, Colon Cancer, Conventional Chondrosarcoma, Developmental and Epileptic Encephalopathy, Dravet Syndrome, Episodic Cluster Headache

Studies at this site

• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) — Recruiting now
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Recruiting now
• A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis — Recruiting now
• A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study — Recruiting now
• Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) — Running, not enrolling
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) — Enrolling by invitation
• Study of INBRX-109 in Conventional Chondrosarcoma — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy — Running, not enrolling
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis — Enrolling by invitation
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers — Completed
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period — Completed
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Running, not enrolling
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks — Completed
• A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache — Completed
• A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early